Literature DB >> 23212753

Asymptomatic progressive multifocal leukoencephalopathy associated with natalizumab.

Eavan M Mc Govern, Michael J Hennessy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23212753     DOI： 10.1007/s00415-012-6759-0

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  6 in total

1.  Progressive multifocal leukoencephalopathy.

Authors:  E P RICHARDSON
Journal:  N Engl J Med       Date:  1961-10-26       Impact factor: 91.245

2.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Gary Bloomgren; Sandra Richman; Christophe Hotermans; Meena Subramanyam; Susan Goelz; Amy Natarajan; Sophia Lee; Tatiana Plavina; James V Scanlon; Alfred Sandrock; Carmen Bozic
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

3.  MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy.

Authors:  Rémy Phan-Ba; Emilie Lommers; Luaba Tshibanda; Philippe Calay; Bernard Dubois; Gustave Moonen; David Clifford; Shibeshih Belachew
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-10-19       Impact factor: 10.154

Review 4.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

5.  Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  P Vermersch; L Kappos; R Gold; J F Foley; T Olsson; D Cadavid; C Bozic; S Richman
Journal:  Neurology       Date:  2011-05-17       Impact factor: 9.910

6.  A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Authors:  Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Journal:  N Engl J Med       Date:  2006-03-02       Impact factor: 91.245
  6 in total
  5 in total

Review 1.  Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab.

Authors:  Caroline Antoniol; Bruno Stankoff
Journal:  Front Immunol       Date:  2015-01-05       Impact factor: 7.561

2.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

3.  Outcome and survival of asymptomatic PML in natalizumab-treated MS patients.

Authors:  Tuan Dong-Si; Sandra Richman; Mike P Wattjes; Made Wenten; Sarah Gheuens; Jeffrey Philip; Shoibal Datta; James McIninch; Carmen Bozic; Gary Bloomgren; Nancy Richert
Journal:  Ann Clin Transl Neurol       Date:  2014-10-09       Impact factor: 4.511

Review 4.  Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group.

Authors:  C McGuigan; M Craner; J Guadagno; R Kapoor; G Mazibrada; P Molyneux; R Nicholas; J Palace; O R Pearson; D Rog; C A Young
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-10-22       Impact factor: 10.154

Review 5.  Asymptomatic progressive multifocal leukoencephalopathy: a case report and review of the literature.

Authors:  Yinan Zhang; Crystal Wright; Angela Flores
Journal:  J Med Case Rep       Date:  2018-07-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.